Inventor · disambiguated record
Eric Benjamin
Also filed as: BENJAMIN ERIC · BENJAMIN ERIC J · BENJAMIN ERIC JOEL
17 granted patents·25 pending applications·338 citations·filing 1981–2024
94Inventor score
Top patents by PatentIndex Score
42 records- 0193US6815424B2Intranasal administration of polypeptides in powdered formPFIZER·Filed 2002·Granted Nov 9, 2004·43 cites·10 claims
- 0290US11957875B2Techniques and devices providing adaptivity and personalization in diabetes treatmentINSULET CORP·Filed 2020·Granted Apr 16, 2024·2 cites·20 claims
- 0390US7981424B2RAGE fusion proteins, formulations, and methods of use thereofTRANSTECH PHARMA INC·Filed 2007·Granted Jul 19, 2011·15 cites·52 claims
- 0487US7759386B2Pharmaceutical compositions of estrogenic agentsWYETH LLC·Filed 2007·Granted Jul 20, 2010·10 cites·3 claims
- 0587US7446111B2Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositionsWYETH CORP·Filed 2007·Granted Nov 4, 2008·12 cites·27 claims
- 0685US4782047AAqueous steroid formulations for nasal administrationSYNTEX PHARMA INT·Filed 1986·Granted Nov 1, 1988·46 cites·15 claims
- 0785US2025288681A1Solid compositions comprising a glucokinase activator and methods of making and using the sameVTV THERAPEUTICS LLC·Filed 2024·Application pending·0 cites
- 0883US10292966B2Sustained release pharmaceutical compositionsWYETH LLC·Filed 2018·Granted May 21, 2019·4 cites·21 claims
- 0981US11179369B2Sustained release pharmaceutical compositionsWYETH LLC·Filed 2019·Granted Nov 23, 2021·1 cites·17 claims
- 1081US10463648B2Sustained release pharmaceutical compositionsWYETH LLC·Filed 2018·Granted Nov 5, 2019·3 cites·28 claims
- 1181US4837239ACardiotonic phosphodiesterase inhibitors complexed with water soluble vitaminsSYNTEX INC·Filed 1986·Granted Jun 6, 1989·69 cites·24 claims
- 1280US7271177B2Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositionsWYETH CORP·Filed 2004·Granted Sep 18, 2007·14 cites·49 claims
- 1377US4382091AStabilization of 1-substituted imidazole derivatives in talcSYNTEX INC·Filed 1981·Granted May 3, 1983·58 cites·10 claims
- 1477US2024185980A1Onboarding and total daily insulin adaptivityINSULET CORP·Filed 2024·Application pending·0 cites
- 1576US9198901B2Tris(hydroxymethyl)aminomethane salts of a small-molecule GLP1R agonist and pharmaceutical compositions and uses thereofTRANSTECH PHARMA LLC·Filed 2014·Granted Dec 1, 2015·4 cites·20 claims
- 1675US11935637B2Onboarding and total daily insulin adaptivityINSULET CORP·Filed 2019·Granted Mar 19, 2024·1 cites·14 claims
- 1774US2023061743A1Sustained release pharmaceutical compositionsWYETH LLC·Filed 2022·Application pending·0 cites
- 1874US2022233701A1Solid compositions comprising a glucokinase activator and methods of making and using the sameVTV THERAPEUTICS LLC·Filed 2021·Application pending·0 cites
- 1973US2024252753A1Techniques and devices providing adaptivity and personalization in diabetes treatmentINSULET CORP·Filed 2024·Application pending·0 cites
- 2070US4983595AAqueous steroid formulations for nasal administrationSYNTEX INC·Filed 1988·Granted Jan 8, 1991·42 cites·1 claims
- 2165US12431229B2Medicament delivery device with an adjustable and piecewise analyte level cost component to address persistent positive analyte level excursionsINSULET CORP·Filed 2022·Granted Sep 30, 2025·0 cites·17 claims
- 2264US2005089480A1Intranasal administration of polypeptides in powdered formFiled 2004·Application pending·0 cites
- 2361US2019046645A1Solid Compositions Comprising a Glucokinase Activator and Methods of Making and Using the SameVTV THERAPEUTICS LLC·Filed 2018·Application pending·0 cites
- 2460US2023310742A1Autonomous adaptivity and set point control for a drug delivery deviceINSULET CORP·Filed 2023·Application pending·0 cites
- 2557US2010062058A1Delayed Release Formulations for Oral Administration of a Polypeptide Therapeutic Agent and Methods of Using SameWYETH CORP·Filed 2009·Application pending·0 cites
- 2656US2021228804A1Meal insulin determination for improved post prandial responseINSULET CORP·Filed 2021·Application pending·0 cites
- 2755US2007082952A1Pharmaceutical compositions, methods of preparation thereof, and methods of treatmentBENJAMIN ERIC J·Filed 2006·Application pending·0 cites
- 2855US2022062546A1Adjusting settings to different degrees of aggressiveness in an automated insulin delivery system based on quality of blood glucose level control by a userINSULET CORP·Filed 2020·Application pending·0 cites
- 2955US2005095292A1Sustained release pharmaceutical compositionsWYETH CORP·Filed 2004·Application pending·0 cites
- 3054US6521597B1Intranasal administration of LHRH polypeptides in powdered formPHARMACIA CORP·Filed 1992·Granted Feb 18, 2003·14 cites·18 claims
- 3153US2004122048A1Stabilized pharmaceutical composition containing basic excipientsWYETH CORP·Filed 2003·Application pending·0 cites
- 3252US2016015816A1Solid compositions comprising a glucokinase activator and methods of making and using the sameVTV THERAPEUTICS LLC·Filed 2015·Application pending·0 cites
- 3351US2004077677A1Oral formulationsWYETH CORP·Filed 2003·Application pending·0 cites
- 3449US2008161336A1Orally bioavailable CCI-779 formulationsWYETH CORP·Filed 2008·Application pending·0 cites
- 3548US2004126358A1Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using sameFiled 2003·Application pending·0 cites
- 3646US2005004079A1Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereofWYETH CORP·Filed 2004·Application pending·0 cites
- 3745US2005142192A1Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivativesWYETH CORP·Filed 2004·Application pending·0 cites
- 3844US2007185204A1Crystalline forms of 3-biphenyl-4-yl-(2S)-[(4'-trifluoromethyl-biphenyl-4-carbonyl)-amino]-propionic acid, and methods of useBENJAMIN ERIC J·Filed 2007·Application pending·0 cites
- 3944US2006183766A1Orally bioavailable CCI-779 formulationsWYETH CORP·Filed 2006·Application pending·0 cites
- 4044US2011064806A1Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the sameTRANSTECH PHARMA INC·Filed 2010·Application pending·0 cites
- 4140US2002031548A1Pharmaceutical compositions of estrogenic agentsAMERICAN HOME PROD·Filed 2001·Application pending·0 cites
- 4240US2005152983A1Directly compressible pharmaceutical composition for the oral administration of CCI-779WYETH CORP·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Eric Benjamin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →